🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Benefits of Retained Insulin for Good Health

Recruitingn/aAges 18 Years - anyAllRoyal Devon and Exeter NHS Foundation Trust
NCT07828626 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The purpose of this research is to understand the impact of retained endogenous insulin (as measured by C-peptide) on quality of life and related outcomes in people living with insulin treated diabetes, and, in those living with type 1 diabetes, to determine the pragmatic and non-pragmatic C-peptide measures which have the strongest association with clinical benefit (including repeated home samples and derived measures of beta cell function). The investigators will do this in two ways: Firstly, the investigators will extend a large existing prospective study of new adult onset diabetes (Getting the Right Classification and Treatment From Diagnosis in Adults With Diabetes (StartRight)) https://clinicaltrials.gov/ct2/show/NCT03737799) which has followed 1800 participants for median 4 years from diabetes diagnosis. Participants with insulin treated diabetes will be invited to take part in

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
ARM 1 Inclusion Criteria: * Previously recruited to the StartRight study (NCT03737799) with consent to be contacted for further research * Clinical diagnosis of diabetes \& Insulin treated * Able and willing to provide informed consent/assent. * Aged 18 years or older. ARM 2 Inclusion Criteria: * Clinical diagnosis of Type 1 diabetes * Known C-peptide, measured as part of previous research or as part of diabetes clinical care OR Where C-peptide is not measured, participant must be within 7 years of diagnosis and have at least 1 positive islet antibody, measured at any time since diabetes diagnosis. * Where measured C-peptide is \>600pmol/L, previous positive islet autoantibodies. * Able and willing to provide informed consent * Aged 18 years or older Exclusion Criteria: \- Renal failure defined by eGFR \<30mL/min/1.73 m²
💊

What it tests

  • Observational
📍

Where

4 sites
Diabetes and Endocrine Centre
Truro, United Kingdom
NIHR Exeter Clinical Research Facility
Exeter, United Kingdom
D1 Wolfson Centre Research and Development
Bath, United Kingdom
Clinical Research Centre
Bristol, United Kingdom
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy